References
- Smalstig E., Clemens J. Dopamine agonist activity of LY163502. The Pharmacologist 1984; 26: 136
- Bach N., Kornfeld E., Jones N., Chaney M., Dorman D., Paschal J., Clemens J. J., Smalstig E. Bicyclic and tricyclic ergoline partial structures. Rigid 3 - (2-aminoethyl) pyroles and 3 - and 4 - (2-aminoethyl)pyrazoles as dopamine agonists. J. Med. Chem. 1980; 23: 481–491
- Foreman M. M., Fuller R. W., Hynes M. D., Gidda J. S., Nichols C. L., Schaus J. M., Kornfeld E. C., Clemens J. A. Preclinical studies on quinelorane, a potent and highly selective D2-dopaminergic agonist. J. Pharmacol. Exp. Therap. 1989; 250: 227–235
- Manzione B. M., Bernstein J. R., Franklin R. B. Observations on the absorption, distribution, metabolism and excretion of the dopamine (D2) agonist, quinelorane, in rats, mice, dogs and monkeys. Drug Metab. Dispos. 1991; 19: 54–60
- Wozniak T. J., Davis S. E., Jansen P. J. Quinelorane transdermal delivery system: (II) Analytical characterization of matrix-type systems AAPS Seventh Annual Meeting, San Antonio, TX, November, 1992, abstract # PDD 7268
- Taber L. D., Apathy J. M., DeLong A. F., Sportsman J. R. Enzyme-linked immunosorbant assay for LY163502, a potent dopamine agonist. J. Pharm. Sci. 1987; 76: 492–495
- Wester R. C., Maibach H. I. “Transdermal Delivery of Drugs”, A. F. Kydonieus, B. Berner. CRC Press, Inc., Boca Raton FloridaUSA 1987; Volume 1: 61–70